Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Filters applied: . Clear all
Page 1
Dose-Intensified Infliximab Rescue Therapy for Severe Ulcerative Colitis Does Not Reduce Short-term Colectomy Rates or Increase Postoperative Complications.
Kosaraju RS, Wong DJ, Roth EM, Cataldo TE, Fabrizio AC, Crowell KT, Feuerstein JD, Messaris E. Kosaraju RS, et al. Among authors: roth em. Dis Colon Rectum. 2022 Oct 1;65(10):1232-1240. doi: 10.1097/DCR.0000000000002176. Epub 2022 Jul 15. Dis Colon Rectum. 2022. PMID: 35714346
MAIN OUTCOME MEASURES: The primary outcome was colectomy rate within 3 months of rescue therapy. Secondary outcomes include mid-term colectomy rates, as well as perioperative complications in patients receiving colectomy within 3 months of rescue infliximab initiation. ...
MAIN OUTCOME MEASURES: The primary outcome was colectomy rate within 3 months of rescue therapy. Secondary outcomes include mid-term …
Temporal trends and impact of willingness to accept organs from donors with hepatitis C virus.
Yuan Q, Cui H, Leya GA, Hong S, Roth EM, Sise ME, Bethea ED, Yeh H, Williams WW, Elias N. Yuan Q, et al. Among authors: roth em. Transpl Int. 2021 Dec;34(12):2562-2569. doi: 10.1111/tri.14152. Epub 2021 Nov 11. Transpl Int. 2021. PMID: 34726801 Free article.
CWTA organs from HCV(+) donors rose significantly with DAA availability, benefitting kidney and liver candidates with increased DDTx rates and shortened kidney candidates' wait time. Further long-term outcomes investigation and standardized organ from HCV(+) donors' educat …
CWTA organs from HCV(+) donors rose significantly with DAA availability, benefitting kidney and liver candidates with increased DDTx rates a …
Long-Term Outcomes of Early Experience in Donation After Circulatory Death Liver Transplantation: Outcomes at 10 Years.
Haque OJ, Roth EM, Fleishman A, Eckhoff DE, Khwaja K. Haque OJ, et al. Among authors: roth em. Ann Transplant. 2021 Apr 20;26:e930243. doi: 10.12659/AOT.930243. Ann Transplant. 2021. PMID: 33875633 Free PMC article.
BACKGROUND Donation after circulatory death (DCD) livers remain an underutilized pool of transplantable organs due to concerns of inferior long-term patient survival (PS) and graft survival (GS), which factors greatly into clinician decision-making and patient expectations …
BACKGROUND Donation after circulatory death (DCD) livers remain an underutilized pool of transplantable organs due to concerns of inferior l …
Patient-Reported Quality-of-Life Outcome Measures in the Thyroid Cancer Population.
Roth EM, Lubitz CC, Swan JS, James BC. Roth EM, et al. Thyroid. 2020 Oct;30(10):1414-1431. doi: 10.1089/thy.2020.0038. Epub 2020 May 14. Thyroid. 2020. PMID: 32292128 Free PMC article.
Further development and rigorous validation of TC-specific instruments will allow for better data gathering and understanding of the barriers to achieving high long-term HRQoL in TC survivors throughout their long postsurvival course....
Further development and rigorous validation of TC-specific instruments will allow for better data gathering and understanding of the barrier …
Relationship between alirocumab, PCSK9, and LDL-C levels in four phase 3 ODYSSEY trials using 75 and 150 mg doses.
Robinson JG, Farnier M, Kastelein JJP, Roth EM, Taskinen MR, Colhoun HM, Brunet A, DiCioccio AT, Lecorps G, Pordy R, Baccara-Dinet MT, Cannon CP. Robinson JG, et al. Among authors: roth em. J Clin Lipidol. 2019 Nov-Dec;13(6):979-988.e10. doi: 10.1016/j.jacl.2019.10.004. Epub 2019 Oct 14. J Clin Lipidol. 2019. PMID: 31708410 Free article. Clinical Trial.
METHODS: Data were analyzed from 4 phase 3 trials (MONO; COMBO II; FH I; LONG TERM); all but MONO enrolled patients on statins. Three trials evaluated alirocumab 75 mg Q2W, with possible dose increase to 150 mg Q2W at week 12 based on week 8 LDL-C; LONG TERM studied …
METHODS: Data were analyzed from 4 phase 3 trials (MONO; COMBO II; FH I; LONG TERM); all but MONO enrolled patients on statins. Three …
Surgery in the age of biologics.
Wong DJ, Roth EM, Feuerstein JD, Poylin VY. Wong DJ, et al. Among authors: roth em. Gastroenterol Rep (Oxf). 2019 Apr;7(2):77-90. doi: 10.1093/gastro/goz004. Epub 2019 Mar 11. Gastroenterol Rep (Oxf). 2019. PMID: 30976420 Free PMC article. Review.
Rates of intestinal resection in patients with Crohn's disease or colectomy in ulcerative colitis are reducing but not substantially over the long term. An increasing variety of biologic medications are now available to treat IBD patients in various clinical situations. .. …
Rates of intestinal resection in patients with Crohn's disease or colectomy in ulcerative colitis are reducing but not substantially over th …
Effects of Xuezhikang in patients with dyslipidemia: a multicenter, randomized, placebo-controlled study.
Moriarty PM, Roth EM, Karns A, Ye P, Zhao SP, Liao Y, Capuzzi DM, Bays HE, Zhang F, Liu S, Reichman AJ, Brusco OA, Lu G, Lerman S, Duan Z, Guo S, Liu PL, Zhao J, Zhang Y, Li S. Moriarty PM, et al. Among authors: roth em. J Clin Lipidol. 2014 Nov-Dec;8(6):568-575. doi: 10.1016/j.jacl.2014.09.002. Epub 2014 Sep 16. J Clin Lipidol. 2014. PMID: 25499939 Clinical Trial.
CONCLUSION: Xuezhikang significantly reduced non-HDL-C and LDL-C, and was well tolerated. Further, longer-term studies in more diverse patient populations are needed to corroborate these findings....
CONCLUSION: Xuezhikang significantly reduced non-HDL-C and LDL-C, and was well tolerated. Further, longer-term studies in more divers …
Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.
Kipnes MS, Roth EM, Rhyne JM, Setze CM, Lele A, Kelly MT, Sleep DJ, Stolzenbach JC. Kipnes MS, et al. Among authors: roth em. Clin Drug Investig. 2010;30(1):51-61. doi: 10.2165/11319800-000000000-00000. Clin Drug Investig. 2010. PMID: 19995098 Clinical Trial.
BACKGROUND AND OBJECTIVES: Long-term (>1 year) safety and efficacy studies of combination lipid therapy are lacking. ...Overall, fenofibric acid + moderate-dose statin for > or =2 years resulted in sustained improvements in HDL-C (+17.4%), TG (-46.4%) and LDL-C (-40. …
BACKGROUND AND OBJECTIVES: Long-term (>1 year) safety and efficacy studies of combination lipid therapy are lacking. ...Overall, f …
Abciximab provides cost-effective survival advantage in high-volume interventional practice.
Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, Roth EM, Whang DD, Cocks D, Abbottsmith CW. Kereiakes DJ, et al. Among authors: roth em. Am Heart J. 2000 Oct;140(4):603-10. doi: 10.1067/mhj.2000.109647. Am Heart J. 2000. PMID: 11011333
METHODS: Consecutive percutaneous coronary interventions (n = 1472) performed by Ohio Heart Health Center operators at The Christ Hospital, Cincinnati, Ohio, in 1997 were analyzed for procedural and long-term (6-month) outcomes and charges. Observations on cost and efficac …
METHODS: Consecutive percutaneous coronary interventions (n = 1472) performed by Ohio Heart Health Center operators at The Christ Hospital, …